Search results for "Unstable"

showing 10 items of 111 documents

Sensitive Troponin I Assay in Early Diagnosis of Acute Myocardial Infarction

2009

BACKGROUND Cardiac troponin testing is central to the diagnosis of acute myocardial infarction. We evaluated a sensitive troponin I assay for the early diagnosis and risk stratification of myocardial infarction. METHODS In a multicenter study, we determined levels of troponin I as assessed by a sensitive assay, troponin T, and traditional myocardial necrosis markers in 1818 consecutive patients with suspected acute myocardial infarction, on admission and 3 hours and 6 hours after admission. RESULTS For samples obtained on admission, the diagnostic accuracy was highest with the sensitive troponin I assay (area under the receiver-operating-characteristic curve [AUC], 0.96), as compared with t…

MaleChest Painmedicine.medical_specialtyMyocardial InfarctionComorbiditySensitivity and SpecificityAnginaElectrocardiographyTroponin TPredictive Value of TestsInternal medicineTroponin ImedicineHumansAngina UnstableMyocardial infarctionAgedbiologymedicine.diagnostic_testbusiness.industryTroponin IHazard ratioGeneral MedicineMiddle Agedmedicine.diseaseTroponinEarly DiagnosisROC CurveArea Under CurvePredictive value of testsbiology.proteinCardiologyFemaleMyocardial infarction diagnosisbusinessElectrocardiographyBiomarkersNew England Journal of Medicine
researchProduct

Prognostic and therapeutic implications of dipyridamole stress cardiovascular magnetic resonance on the basis of the ischaemic cascade

2008

To determine the prognostic and therapeutic implications of stress perfusion cardiovascular magnetic resonance (CMR) on the basis of the ischaemic cascade.Single centre study in a teaching hospital in Spain.Dipyridamole stress CMR was performed on 601 patients with ischaemic chest pain and known or suspected coronary artery disease. On the basis of the ischaemic cascade, patients were categorised in C1 (no evidence of ischaemia, n = 354), C2 (isolated perfusion deficit at stress first-pass perfusion imaging, n = 181) and C3 (simultaneous perfusion deficit and inducible wall motion abnormalities, n = 66). CMR-related revascularisation (n = 102, 17%) was defined as the procedure prompted by t…

MaleChest Painmedicine.medical_specialtyPerfusion ImagingVasodilator AgentsPerfusion scanningCoronary Artery DiseaseChest painMagnetic resonance angiographyCoronary artery diseaseInternal medicineMyocardial RevascularizationmedicineHumanscardiovascular diseasesmedicine.diagnostic_testbusiness.industryUnstable anginaDipyridamoleMiddle AgedPrognosismedicine.diseaseDipyridamoleExercise TestCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessPerfusionMagnetic Resonance AngiographyMacemedicine.drugHeart
researchProduct

Guideline-adherence regarding critical time intervals in the German Chest Pain Unit registry

2020

Background: Since 2008, the German Cardiac Society certified 256 Chest Pain Units (CPUs). Little is known about adherence to recommended performance measures in patients with suspected acute coronary syndrome (ACS) presenting to CPUs. We investigated guideline-adherence regarding critical time intervals and selected performance measures in German Chest Pain Units. Methods: From 2008 to 2014, 23,804 consecutive patients with suspected ACS were prospectively enrolled in the Chest Pain Unit registry of the German Cardiac Society. Results: Median time from symptom onset to first medical contact was 2 h in patients with ST-elevation myocardial infarction (STEMI) and 4 h in patients with unstable…

MaleCritical timeMedizinische Fakultät » Universitätsklinikum Essen » Institut für PathophysiologieTime FactorsMedizin030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineChest painGermanElectrocardiography610 Medical sciences Medicine0302 clinical medicineGermanyProspective StudiesRegistries030212 general & internal medicineNon-ST Elevated Myocardial InfarctionGuideline adherenceGeneral MedicineMiddle AgedHospitalizationlanguageFemaleAcute coronary syndromeGuideline Adherencemedicine.symptomCardiology and Cardiovascular MedicineHospital UnitsChest Painmedicine.medical_specialtyAcute coronary syndromeguideline-adherence61003 medical and health sciencesPercutaneous Coronary Interventiontime intervalsmedicineHumansIn patientddc:610Angina Unstablecardiovascular diseasesAcute Coronary SyndromeAgedbusiness.industryUnstable anginamedicine.diseaseChest Pain Unitlanguage.human_languageEmergency medicineExercise TestST Elevation Myocardial InfarctionTomography X-Ray ComputedbusinessEuropean Heart Journal: Acute Cardiovascular Care
researchProduct

Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease

2005

Background -The underlying mechanism of the chronic inflammatory process in atherosclerosis is still unknown. As a possible trigger, several studies in recent years have suggested that different viruses and bacteria are associated with atherosclerotic diseases. Methods - We applied polymerase chain reaction to analyse whether Epstein-Barr virus (EBV), herpes simplex virus (HSV), and cytomegalovirus (CMV) DNA could be detected in CD14 + cells from 184 patients with angiographically documented coronary artery disease (CAD) (74 patients with stable angina (SAP), 51 patients with unstable angina (UAP), and 59 patients with myocardial infarction (Ml)) and from 52 healthy controls. Results - In t…

MaleHerpesvirus 4 HumanMolecular Sequence DataCytomegalovirusCoronary Artery Diseasemedicine.disease_causePolymerase Chain ReactionRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexVirusAngina Pectorislaw.inventionCoronary artery diseaseSex FactorslawHumansSimplexvirusMedicineAngina UnstableCoronary atherosclerosisPolymerase chain reactionAgedProbabilityAnalysis of VarianceBase Sequencebusiness.industryUnstable anginaIncidenceAge FactorsCytomegalovirusGeneral MedicineMiddle AgedPrognosismedicine.diseaseEpstein–Barr virusVirologyHerpes simplex virusCase-Control StudiesDNA ViralImmunologyFemaleCardiology and Cardiovascular MedicinebusinessActa Cardiologica
researchProduct

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-l…

2009

Udgivelsesdato: 2009-Jun-20 BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. METHODS: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A(1c) (HbA(1c)) of 7.9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active con…

MaleMyocardial InfarctionAdministration OralType 2 diabeteslaw.inventionFractures BoneRandomized controlled triallawNeoplasmsClinical endpointMyocardial infarctionrosiglitazone; cardiovascular outcomesProspective StudiesDiureticsGeneral MedicineMiddle AgedMetforminMetforminHospitalizationStrokeDrug Therapy CombinationFemaleRosiglitazonemedicine.drugmedicine.medical_specialtyRosiglitazoneSex FactorsInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsAngina UnstableDiabetes Rosiglitazone Cardiovascular RiskHemoglobin A GlycosylatedGlycated HemoglobinHeart FailureIntention-to-treat analysisbusiness.industryBody WeightCholesterol HDLCholesterol LDLtype 2 diabetes; rosiglitazonemedicine.diseaseDrug UtilizationSurgerySulfonylurea CompoundsDiabetes Mellitus Type 2ThiazolidinedionesHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessLancet (London, England)
researchProduct

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome

2015

BACKGROUND: Cardiovascular morbidity and mortality are higher among patients with type 2 diabetes, particularly those with concomitant cardiovascular diseases, than in most other populations. We assessed the effects of lixisenatide, a glucagon-like peptide 1-receptor agonist, on cardiovascular outcomes in patients with type 2 diabetes who had had a recent acute coronary event.METHODS: We randomly assigned patients with type 2 diabetes who had had a myocardial infarction or who had been hospitalized for unstable angina within the previous 180 days to receive lixisenatide or placebo in addition to locally determined standards of care. The trial was designed with adequate statistical power to …

MaleMyocardial InfarctionKaplan-Meier Estimate2700 General MedicineType 2 diabetesAnginachemistry.chemical_compoundTreatment FailureMyocardial infarctionResearch Support Non-U.S. Gov'tHemoglobin AGeneral MedicineAnginaMiddle AgedMulticenter StudyCardiovascular DiseasesRandomized Controlled TrialCardiologyFemalelixisenatideType 2medicine.medical_specialtyAcute coronary syndromeGlycosylated610 Medicine & healthUnstableGlucagon-Like Peptide-1 Receptor11171 Cardiocentro TicinoLixisenatideAcute Coronary Syndrome; Aged; Angina Unstable; Cardiovascular Diseases; Diabetes Mellitus Type 2; Female; Glucagon-Like Peptide-1 Receptor; Hemoglobin A Glycosylated; Humans; Hypoglycemic Agents; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Peptides; Proportional Hazards Models; Treatment FailureInternal medicineJournal ArticleDiabetes MellitusmedicineHumansHypoglycemic AgentsAngina UnstableAcute Coronary SyndromeAgedProportional Hazards ModelsHemoglobin A GlycosylatedUnstable anginabusiness.industrySemaglutideta3121medicine.diseaseDiabetes Mellitus Type 2chemistryMyocardial infarction complicationsPeptidesbusinessNew England Journal of Medicine
researchProduct

Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery di…

2008

Summary. Background: Thrombin activatable fibrinolysis inhibitor (TAFI) attenuates fibrinolysis. Results on the association between TAFI levels and the risk of coronary artery disease (CAD) are inconsistent. Objectives: We investigated the association between TAFI levels and the risk of cardiovascular events in CAD. Patients/Methods: 1668 individuals with angiographically proven CAD at baseline were followed for a median of 2.3 years, as part of the prospective AtheroGene cohort. Fifty-six deaths from cardiovascular (CV) causes and 35 non-fatal CV events were observed. Results: At baseline, three TAFI measurements were available: one evaluating the total amount of TAFI (t-TAFI), one measuri…

MaleRiskCarboxypeptidase B2medicine.medical_specialtymedicine.medical_treatmentCoronary Artery DiseaseCoronary artery diseaseRisk FactorsInternal medicineFibrinolysismedicineHumansMyocardial infarctionAgedProportional Hazards Modelsbusiness.industryUnstable anginaProportional hazards modelHazard ratioHematologyMiddle Agedmedicine.diseaseCarboxypeptidase BDeath Sudden CardiacCohortCardiologyFemalebusinessProtein Cmedicine.drugJournal of Thrombosis and Haemostasis
researchProduct

Glutathione Peroxidase 1 Activity and Cardiovascular Events in Patients With Coronary Artery Disease

2003

Along with superoxide dismutase, glutathione peroxidase 1 is one of the cellular antioxidant enzymes that have a key role in controlling reactive oxygen species. It uses glutathione to reduce hydrogen peroxide to water and lipid peroxides to their respective alcohols. There are suggestions from in vitro and animal studies that these enzymes could protect against atherosclerosis. This prospective study examined the possibility that relatively high activity of antioxidant enzymes protects against cardiovascular events. The study population included 636 patients suspected of having coronary artery disease who were followed for a median period of 4.7 years. Stable angina was present in 510 pati…

MaleRiskmedicine.medical_specialtyGPX1ErythrocytesAntioxidantmedicine.medical_treatmentCoronary Artery DiseaseGastroenterologyCoronary artery diseaseSuperoxide dismutasechemistry.chemical_compoundSex FactorsInternal medicinemedicineHumansProspective StudiesMyocardial infarctionRisk factorAgedchemistry.chemical_classificationAnalysis of VarianceGlutathione PeroxidaseReactive oxygen speciesbiologySuperoxide DismutaseUnstable anginabusiness.industryGlutathione peroxidaseSmokingObstetrics and GynecologyGeneral MedicineGlutathionemedicine.diseaseSurvival AnalysisEndocrinologychemistryCardiovascular Diseasesbiology.proteinFemalebusinessBiomarkersPeroxidaseObstetrical & Gynecological Survey
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effects of unstable shoes on trunk muscle activity in patients with chronic low back pain

2018

Este artículo se encuentra disponible en la página web de la revista en la siguiente URL: https://www.sciencedirect.com/science/article/abs/pii/S0966636218307252?via%3Dihub En este artículo científico también participan los siguientes autores: María Dolores Arguisuelas, Julio Doménech-Fernández, Daniel Sánchez-Zuriaga, Juan José Amer-Cuenca, Javier Martínez-Gramage, Francisco Javier Montañez-Aguilera y Juan Francisco Lisón. Este es el pre-print del siguiente artículo: Salvador Coloma, P., Arguisuelas, MD., Doménech-Fernández, J., Sánchez-Zuriaga, D., Amer-Cuenca, JJ., Martínez-Gramage, J. et al. (2018). Effects of unstable shoes on trunk muscle activity in patients with chronic low back pai…

MaleWalkingElectromyography0302 clinical medicineOrthopedics and Sports MedicineTreadmillGaitBackache - Treatment.Spine - Electromyography.030222 orthopedicsmedicine.diagnostic_testRehabilitationTorsoMiddle AgedLow back painTrunk musclesRoland Morris Disability QuestionnaireFemaleChronic Painmedicine.symptomAbdomen - Electromiografía.Adultmedicine.medical_specialtyAdolescentAbdomen - Electromyography.BiophysicsYoung Adult03 medical and health sciencesPhysical medicine and rehabilitationmedicineHumansLow back painMuscle SkeletalAgedChronic pain - Treatment.Arthrometry ArticularElectromyographybusiness.industryUnstable shoes030229 sport sciencesGaitSpineShoesDolor crónico - Tratamiento.Cross-Sectional StudiesLumbago - Tratamiento.Gait analysisOrthopedic surgeryExercise TestColumna vertebral - Electromiografía.Trunk musclebusinessLow Back Painhuman activities
researchProduct